Newman Ferrara LLP Announces Corporate Governance Investigation of Abeona Therapeutics Inc. ABEO

Newman Ferrara LLP announced today that the firm is conducting an
investigation on behalf of stockholders of Abeona Therapeutics Inc.
(“Abeona” or the “Company”) (NASDAQ: ABEO) into potential breaches of
fiduciary duty by the Company’s Board of Directors (the “Board”).

Abeona, headquartered in Dallas, Texas, is a clinical-stage
biopharmaceutical company that develops gene therapy products for rare
diseases. Newman Ferrara’s investigation focuses on decisions made by
the Board, without shareholder approval, the result of which
significantly diminish shareholder value and do not benefit the Company.
Considering the Abeona’s poor performance and mounting losses, it is
clear that the Board lacks the ability to fairly assess and oversee the
Company’s direction and leadership.

Current Abeona stockholders seeking more information on this matter are
invited to contact Newman Ferrara attorneys Jeffrey Norton (jnorton@nfllp.com)
or Ryan Jerome (rjerome@nfllp.com)
to discuss this investigation and their rights.

Newman Ferrara maintains a multifaceted practice based in New York City
with attorneys specializing in complex commercial and multi-party
litigation, securities fraud and shareholder litigation, consumer
protection, civil rights, and real estate. For more information, please
visit the firm website at www.nfllp.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180618006156/en/